Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55-70 Years): Findings from a Randomised Double-Blinded Controlled Trial

What Was Tested

This randomized controlled trial paper looks at IGF-1 LR3.

Objective: To investigate the effects of pomegranate extract on telomere length and serum IGF-1 levels in older adults aged 55-70 years.

Why It Was Studied

At baseline, week 6 and week 12, anthropometric measurements, blood pressure readings and blood samples were collected.

Results: A total of 72 participants completed the study.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind IGF-1 LR3 study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with IGF-1 LR3 could be set against what happens without it.

The IGF-1 LR3 group and the comparison group ran side by side rather than switching.

Telomere length and serum IGF-1 levels were assessed.

What Was Measured

At baseline, week 6 and week 12, anthropometric measurements, blood pressure readings and blood samples were collected.

The subject headings attached to it are Pomegranate, Insulin-Like Growth Factor I, Plant Extracts, Telomere and Antioxidants.

Author keywords: IGF-1, ageing, polyphenols, pomegranate extract and telomere length.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of IGF-1 LR3.

The publication is from 2025 (Nutrients), a journal based in Switzerland.

More context: the IGF-1 LR3 compound page, all human trials.